ICANS After CAR ‐T Therapy: Mechanisms and Management With a Focus on Corticosteroid‐Refractory ICANS
Immunology · 2026
DOI: 10.1111/imm.70171 ↗At a glance
Übersichtsarbeit in Immunology, 2026. Written by Zhengfeng Hou and 7 co-authors. Institution: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Major MEDLINE topics: Immunotherapy, Adoptive, Adrenal Cortex Hormones, Neurotoxicity Syndromes, Receptors, Chimeric Antigen. 130 references. Funded by: National Natural Science Foundation of China, Clinical Trial Initiative Projects of The First Affiliated Hospital of Anhui Medical University, Scientific Research Project of Anhui Provincial Health Commission.
Abstract (original language)
Chimeric antigen receptor T (CAR‐T) cell therapy has transformed the treatment of relapsed or refractory haematologic malignancies, but immune effector cell‐associated neurotoxicity syndrome (ICANS) remains a major and potentially life‐threatening complication. Although most patients with ICANS improve after standard corticosteroid therapy, a subset shows insufficient improvement or neurological deterioration after corticosteroid initiation, a clinical scenario often described as corticosteroid‐refractory or steroid‐refractory ICANS. ICANS develops through a cascade initiated by CAR‐T cell expansion and systemic cytokine release, followed by endothelial activation, blood–brain barrier disruption, glial‐driven neuroinflammation, and neuronal injury. This process may be further amplified by on‐target off‐tumour effects and extracellular vesicles released from CAR‐T cells. ICANS risk is influenced by CAR construct design, target antigen, and disease context. Several tools may contribute to multimodal risk assessment, including the Immune Effector Cell‐Associated Encephalopathy (ICE) score, EASIX/m‐EASIX, ICANS‐PSS, CART‐NS, cytokine profiles, neurofilament light chain, electroencephalography, and imaging, although their predictive value requires further validation. This review summarises the cytokine‐mediated mechanisms, product‐specific risk patterns, and early recognition strategies of ICANS after CAR‐T cell therapy. It also critically appraises emerging investigational approaches for corticosteroid‐refractory ICANS, including cytokine‐directed interventions, endothelial‐stabilising strategies, tyrosine kinase inhibition, CAR‐T cell depletion, intrathecal therapy, and engineered suicide gene systems.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
ORCID profiles: Jian Ge, Zhangbiao Long
Funding
- National Natural Science Foundation of China
- Clinical Trial Initiative Projects of The First Affiliated Hospital of Anhui Medical University
- Scientific Research Project of Anhui Provincial Health Commission
- Research Fund of Anhui Institute of Translational Medicine
- Clinical Science Fund of Anhui Medical University
Cite
APA
Hou, Z., Jin, Y., Ruan, M., Jiang, Y., Fu, Y., Yang, J., Ge, J., & Long, Z. (2026). ICANS After CAR ‐T Therapy: Mechanisms and Management With a Focus on Corticosteroid‐Refractory ICANS. Immunology. https://doi.org/10.1111/imm.70171
Vancouver
Hou Z, Jin Y, Ruan M, Jiang Y, Fu Y, Yang J, et al. ICANS After CAR ‐T Therapy: Mechanisms and Management With a Focus on Corticosteroid‐Refractory ICANS. Immunology. 2026. doi:10.1111/imm.70171
BibTeX
@article{Hou2026,
author = {Hou, Zhengfeng and Jin, Yutong and Ruan, Min and Jiang, Yanli and Fu, Yi and Yang, Jichun and Ge, Jian and Long, Zhangbiao},
title = {ICANS After CAR ‐T Therapy: Mechanisms and Management With a Focus on Corticosteroid‐Refractory ICANS},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70171}
}
EUVIMED